Clinical Trials Logo

Clinical Trial Summary

Cinobufacini has the effects of anticancer, improving the liver function, elevation of immunity and little side effects, and is important and significant for the patients with hepatitis, liver cirrhosis and hepatomas.

Compared with transarterial chemoembolization (TACE) , the clinical effect of cinobufacini is non-inferior/ equivalent.Compared with TACE, cinobufacini is superior in security .


Clinical Trial Description

Inclusion criterion :

1. The sex does not limit, age:18-70 years old .

2. The patients have inoperable advanced hepatoma without serious disorder in liver and renal, tumor occupation< 70 %

3. The patients have failure in surgical intervention or resection operation recidivist

4. Hepatic function Child-pugh A、B

5. All the cases have the definite final diagnosis of imageology results such as MRI、CT 、B ultrasonic or cytology results

6. The patient's prediction of live time>6 months, who can tolerant of TACE and has quality of life ECOG score<3

7. The patients participate the clinical trial voluntarily and have already signed informed consent

Exclusion criterion :

1. Main portal vein was obstructed completely.

2. The occupation of tumor are 70 % or more than 70 % in the whole liver

3. The patient has TACE or other antineoplaston

4. After carcinosectomy the patient has the prophylactic

5. The patient is with renal inadequacy: Cr≥133 umol/L

6. Severe cardiovascular disease

7. The patient is with other diseases to influence the proposal ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01236690
Study type Interventional
Source Changhai Hospital
Contact
Status Recruiting
Phase Phase 2
Start date November 2010
Completion date November 2013

See also
  Status Clinical Trial Phase
Withdrawn NCT04546802 - HepATocellular Cancer Hcv Therapy Study Phase 3
Recruiting NCT03941626 - Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies Phase 1/Phase 2
Completed NCT04920019 - Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery N/A
Recruiting NCT01298284 - A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Phase 4
Terminated NCT02460991 - A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma Phase 3
Completed NCT00539643 - Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma Phase 2
Terminated NCT02704130 - TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma N/A
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2
Completed NCT02191878 - Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Withdrawn NCT01618253 - Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma Phase 1
Terminated NCT00669136 - Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma Phase 1
Completed NCT00861783 - Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma Phase 1
Completed NCT04310709 - Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma Phase 2
Withdrawn NCT02174575 - Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Phase 4
Active, not recruiting NCT00290316 - Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Phase 2
Terminated NCT00503867 - SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma N/A
Active, not recruiting NCT04567615 - A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Phase 2
Completed NCT00877136 - A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Completed NCT00844883 - Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma Phase 2
Completed NCT01306058 - Sorafenib and TRC105 in Hepatocellular Cancer Phase 1/Phase 2